...
首页> 外文期刊>Neoplasia: an international journal for oncology research >SIRT2 Promotes the Migration and Invasion of Gastric Cancer through RAS/ERK/JNK/MMP-9 Pathway by Increasing PEPCK1-Related Metabolism 1 2
【24h】

SIRT2 Promotes the Migration and Invasion of Gastric Cancer through RAS/ERK/JNK/MMP-9 Pathway by Increasing PEPCK1-Related Metabolism 1 2

机译:SIRT2通过增加PEPCK1相关代谢通过RAS / ERK / JNK / MMP-9途径促进胃癌的迁移和侵袭 1 < / sup> 2

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Metastasis is the most important feature of gastric cancer (GC) and the most widely recognized reason for GC-related deaths. Unfortunately, the underlying mechanism behind this metastasis remains unknown. Mounting evidence suggests the dynamic regulatory role of sirtuin2 (SIRT2), a histone deacetylase (HDAC), in cell migration and invasion. The present study aims to evaluate the biological function of SIRT2 in GC and identify the target of SIRT2 as well as evaluate its therapeutic efficacy. We found that SIRT2 was upregulated in GC tissues compared to adjacent normal tissues, and this was correlated with reduced patient survival. Although CCK8 and colony-formation assays showed that SIRT2 overexpression marginally promoted proliferation in GC cell lines, SIRT2 knockdown or treatment with SirReal2 decreased the migration and invasion of GC cells. We demonstrated both in vitro and in vivo that SirReal2 could inhibit the deacetylation activity of SIRT2 and its downstream target PEPCK1, which is related to mitochondrial metabolism and RAS/ERK/JNK/MMP-9 pathway. Taken together, these results demonstrate for the first time that SirReal2 selectively targets SIRT2 and decreases migration as well as invasion in human GC cells. SirReal2 therefore shows promise as a new drug candidate for GC therapy.
机译:转移是胃癌(GC)的最重要特征,也是与GC相关的死亡的最广泛公认的原因。不幸的是,这种转移背后的潜在机制仍然未知。越来越多的证据表明,组蛋白脱乙酰基酶(HDAC)sirtuin2(SIRT2)在细胞迁移和侵袭中的动态调节作用。本研究旨在评估SIRT2在GC中的生物学功能,确定SIRT2的靶标并评估其治疗效果。我们发现,与邻近的正常组织相比,GC组织中的SIRT2上调,这与患者生存期缩短有关。尽管CCK8和集落形成试验表明SIRT2的过表达在一定程度上促进了GC细胞的增殖,但是SIRT2的抑制或SirReal2的处理降低了GC细胞的迁移和侵袭。我们在体外和体内均证明SirReal2可以抑制SIRT2及其下游靶标PEPCK1的脱乙酰活性,这与线粒体代谢和RAS / ERK / JNK / MMP-9途径有关。综上所述,这些结果首次证明,SirReal2选择性靶向SIRT2,并减少了人类GC细胞的迁移和侵袭。因此,SirReal2有望成为GC治疗的新药候选者。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号